Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting — Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for treatment of solid tumor...

PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its...